Our results show that the combination therapy inhibited tumor growth at the contralateral as well as the injected tumor sites by promoting the accumulation of tumor-specific CD8+ T cells followed by DTA-1-mediated depletion of CD4+ Foxp3+ Treg cells. This evidence concerns the gene CD8A and neoplasm.